Inhaled Nitric Oxide Therapy – Community Plan Medical Policy
UnitedHealthcare Community Plan medical policy CS173.K defines clinical indications, exclusions, evidence summary, and applicable coding for inhaled nitric oxide (iNO) therapy in neonates and infants; includes recommendations for term/near-term infants, preterm infants, congenital diaphragmatic hernia (CDH), and postoperative pulmonary hypertension management in infants. This part (1 of 2) contains coverage rationale, clinical evidence, guidelines, FDA approvals, definitions, and one CPT reference.
No material clinical or coverage changes in this update (no material change noted).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.